Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a quick PCR test speed up lifesaving fungal infection diagnosis?

NCT ID NCT04874441

Diagnosis Sponsor: University Hospital, Toulouse Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 11, 2026 · Last updated Aug 12, 2026 · Updated 1 time

Summary

This pilot study explores whether a PCR-based test can deliver faster results for diagnosing invasive candidiasis in intensive care patients. The trial compares the time to results using this new strategy against standard methods, with the hope of enabling earlier, more targeted antifungal treatment. Participants are non-neutropenic ICU patients with suspected candidiasis who are already receiving empirical echinocandin therapy.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
A PCR-based diagnostic test for Candida glabrata and krusei
What this could lead to
If successful, this faster diagnostic approach could help ICU patients get the right antifungal treatment sooner, potentially reducing drug resistance and healthcare costs.
What could go wrong
This is a small pilot study, so results may not apply broadly. The test's accuracy and impact on patient outcomes remain uncertain.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

48 people

The number who actually took part.

Started

May 2022

Finished

Apr 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patient affiliated or benefiting from a social protection system * Patient (or his/her trusted person) having given free and informed written consent to the investigating physician * Non-neutropenic patient hospitalised in the Toulouse University Hospital intensive care unit. * Patient with suspected invasive candidiasis for whom a blood culture for fungal infection diagnosis was taken and for whom an empirical treatment with echinocandin at an adapted dose was implemented. Exclusion Criteria: * Patients under guardianship or trusteeship, persons under court protection * Pregnant or breastfeeding patients.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Candida are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

candidemia candidiasis disseminated candidiasis Torulopsis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Candida

Contacts and locations

Locations

  • Uh Toulouse

    Toulouse, Occitanie, 31000, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.